September 13, 2013
Hisamitsu Pharmaceutical announced on September 11 that it has started a PII clinical study of its idiopathic restless legs syndrome (RLS) treatment HP-3000 (ropinirole HCl) in Japan. The study will evaluate the safety and efficacy of HP-3000 in moderate to...read more